Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply
Aliment Pharmacol Ther
.
2017 May;45(9):1284.
doi: 10.1111/apt.14054.
Authors
U Mahadevan
1
,
S Vermeire
2
,
K Lasch
3
,
B Abhyankar
4
,
F Bhayat
4
,
A Blake
4
,
M Dubinsky
5
Affiliations
1
Center for Colitis and Crohn's Disease, University of California San Francisco, San Francisco, CA, USA.
2
University Hospital Gasthuisberg, Leuven, Belgium.
3
Takeda Pharmaceuticals USA, Inc., Deerfield, IL, USA.
4
Takeda Development Centre Europe Ltd, London, UK.
5
Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
PMID:
28370036
DOI:
10.1111/apt.14054
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antibodies, Monoclonal, Humanized*
Colitis, Ulcerative*
Female
Humans
Pregnancy
Substances
Antibodies, Monoclonal, Humanized
vedolizumab